401 related articles for article (PubMed ID: 26087328)
21. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging.
Sano K; Okada M; Hisada H; Shimokawa K; Saji H; Maeda M; Mukai T
Biol Pharm Bull; 2013; 36(4):602-8. PubMed ID: 23546294
[TBL] [Abstract][Full Text] [Related]
22. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
23. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
24. Targeting of MMP2 activity in malignant tumors with a 68Ga-labeled gelatinase inhibitor cyclic peptide.
Liu Q; Pan D; Cheng C; Zhang A; Ma C; Wang L; Zhang D; Liu H; Jiang H; Wang T; Xu Y; Yang R; Chen F; Yang M; Zuo C
Nucl Med Biol; 2015 Dec; 42(12):939-44. PubMed ID: 26344861
[TBL] [Abstract][Full Text] [Related]
25. [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation.
Knetsch PA; Zhai C; Rangger C; Blatzer M; Haas H; Kaeopookum P; Haubner R; Decristoforo C
Nucl Med Biol; 2015 Feb; 42(2):115-22. PubMed ID: 25459110
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
27. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
[TBL] [Abstract][Full Text] [Related]
28. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
29. PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.
Dijkgraaf I; Yim CB; Franssen GM; Schuit RC; Luurtsema G; Liu S; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):128-37. PubMed ID: 20857099
[TBL] [Abstract][Full Text] [Related]
30.
Siitonen R; Peuhu E; Autio A; Liljenbäck H; Mattila E; Metsälä O; Käkelä M; Saanijoki T; Dijkgraaf I; Jalkanen S; Ivaska J; Roivainen A
J Nucl Med; 2019 Oct; 60(10):1380-1387. PubMed ID: 30850498
[TBL] [Abstract][Full Text] [Related]
31. Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor
Effendi N; Mishiro K; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374773
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
[TBL] [Abstract][Full Text] [Related]
33.
Ren J; Zhu S; Zhang G; Tan X; Qiu L; Lin J; Jiang L
Mol Pharm; 2022 Jul; 19(7):2620-2628. PubMed ID: 35674464
[TBL] [Abstract][Full Text] [Related]
34. PET-Based Human Dosimetry of the Dimeric αvβ3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis.
López-Rodríguez V; Galindo-Sarco C; García-Pérez FO; Ferro-Flores G; Arrieta O; Ávila-Rodríguez MA
J Nucl Med; 2016 Mar; 57(3):404-9. PubMed ID: 26585063
[TBL] [Abstract][Full Text] [Related]
35. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
36. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.
Fellner M; Biesalski B; Bausbacher N; Kubícek V; Hermann P; Rösch F; Thews O
Nucl Med Biol; 2012 Oct; 39(7):993-9. PubMed ID: 22633217
[TBL] [Abstract][Full Text] [Related]
37. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.
Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z
J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048
[TBL] [Abstract][Full Text] [Related]
39. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
40. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
